If you follow hair loss news, you’ve probably seen the headlines: New drug regrows hair by 539%. The news has exploded across social media and news outlets, with many hailing it as the long-awaited cure for baldness. The company behind the drug, known as Clascoterone or Breezula, saw its stock price rise by 40%. On the surface, it sounds like the miracle we’ve all been waiting for. After all, if the current gold standard, finasteride, increases hair counts by about 9%, then a 539% increase should change the world, right? You may be tempted to ditch your current treatments and wait for this game-changer to hit the market.
But not so fast. As with many things that seem too good to be true, there is a big problem. This staggering 539% figure is highly misleading, and company data, both new and old, tells a very different story. In this article, we’ll pull back the curtain on clascoteron. We’ll break down this headline-grabbing number, look at clinical data that drugmakers may not want you to see, and give you a realistic picture of what this new treatment can and can’t do. My goal is to help you navigate the often confusing world of hair loss treatments so you can make the best decisions for your hair and health. (Based on insights from Rob English)
Key takeaways
- The widely reported “539% hair increase” from Clascoterone is not an absolute increase. It is a misleading statistic that compares its small effect to the smaller effect of placebo.
- Previous clinical trials showed that clascoterone was less effective than minoxidil, a common over-the-counter hair loss treatment.
- The before-and-after photos the company posted are disappointing and likely represent the absolute best results from a study of 1,500 people.
- Patients’ self-ratings of hair growth were poor, with one of the two main studies failing to show a statistically significant improvement.
- You should not delay or stop using proven hair loss treatments such as finasteride or minoxidil while waiting for clascoterone to become available.
1. What is clascoterone? The basics explained
First, let’s understand what this drug actually is. Clascoterone is a topical medication, which means you can apply it directly to your scalp. It acts as an androgen receptor antagonist. Consider that your hair follicle cells contain small landing pads (receptors) for male hormones (androgens) such as DHT (dihydrotestosterone). In androgenic alopecia (hair loss in both males and females), DHT binds to these receptors and stimulates the process of hair follicle miniaturization, leading to thinning hair and baldness.
Clascoterone works by blocking these landing pads. If DHT cannot bind to the cell, it will not be able to send a signal to shrink the hair follicle. The big appeal is that it is designed to work locally on the scalp with minimal absorption into the rest of the body, which may mean fewer systemic side effects. In fact, a 1% version of this drug has already been approved by the US Food and Drug Administration to treat acne in teens, indicating a strong safety profile.
2. The 539% claim: Why it’s not what you think it is
This is the most important part to understand. The press release did mention that clascoterone caused a 539% increase in hair from your baseline. She said the increase amounted to 539%. Relative to placebo. This seems like a small difference in wording, but it’s a big difference.
Let me show you how this statistical trick works. Imagine a study where the placebo group (using a dummy treatment) starts with 100 hairs and ends with 101 hairs after six months. This is only an increase One hair. Now imagine that the group of clascoterones begins with 100 hairs and ends with 106 hairs. That’s an increase Six hairs.
If you compare the effect of the drug (+6 hair) with the effect of the placebo (+1 hair), you can say that the drug was 600% more effective than the placebo. This is how they arrive at a number like 539%. The actual absolute change may be cosmetically minimal, but the percentage looks amazing. The company intentionally left out the absolute hair count changes in its press release, which is a big red flag. As we know, real change can be a handful of hair, not the glamorous hair that the headlines suggest.
3. A look back: clascoterone vs. minoxidil
This is not the first time clascoterone has been studied Hair loss. More than seven years ago, before it was acquired by the current company, Clascoterone was tested against minoxidil (Rogaine), one of the two mainstays approved by the FDA for the treatment of hair loss.
In one study in men, clascoterone beat placebo by 5%, which is good. However, 5% minoxidil is superior to clascoterone. The absolute increase in hair number with clascoterone was about 12 hairs, a far cry from 539%. In another study in women, clascoterone did not even outperform placebo, but minoxidil did. These older studies begin to paint a picture of a treatment that, while it may have some effect, is likely not as powerful as the treatments we already have.
4. Pecking order: Clascoterone is classified among hair loss treatments
Based on the available data, we can begin to build a hierarchy of effectiveness of topical treatments. We know from multiple studies that finasteride is generally more effective long-term than minoxidil. We also know that minoxidil works faster than finasteride but its effects can diminish after the first year. From past experiences, we know that minoxidil appears to be more effective than clascoterone.
Therefore, the hierarchy looks like this:
Finasteride > Minoxidil > Clascoterone
While clascoterone could be a useful addition, especially for those who cannot tolerate other treatments, it is unlikely to outperform the current gold standards. It’s a smaller punch, not a bald knockout.
5. A picture is worth a thousand words…or is it?
To drum up excitement, the company released before-and-after photos of two participants in the 1,500-person trial. You have to assume that these are the best and most impressive results they can find. Frankly, they’re disappointing.
The photos show what may be very slight thickness improvements or simple filling of the crown. They’re nowhere near the kind of regrowth that people see in the wonderful responses to finasteride or minoxidil. When a company shows you their best results and your reaction is, “I guess I see a little difference?” It tells you a lot. The average result will be less noticeable. In addition, patient self-assessment data were poor. In one study, the patients themselves weren’t even sure whether the treatment was working in a statistically significant way.
6. How to “Cheat” a Hair Loss Study (And Why You Should Be Skeptical)
As a consumer, it’s helpful to know how study results can be manipulated to seem better than they are. One way is to abuse the “law of small numbers.” If you measure hair growth in a nearly bald area that only has 5 hairs, and the treatment only results in 2 more hairs to grow, that’s a 40% increase! If you did the same thing to someone with 100 hairs, growing two additional hairs would only represent a 2% increase. By selecting participants with advanced hair loss or measuring in the baldest areas, researchers can achieve large percentage gains from small, cosmetically meaningless results.
The other trick is to change the definition of what counts as “real” poetry. Studies can either only count thick, terminal hair or combine it with vellus hair (the soft, invisible “peach fuzz”). Including vellus hair can dramatically amplify hair numbers without adding any visible density. While the clascoterone trial claims to measure “non-vellus” hair, it does not specify its threshold, leaving a loophole for questionable data.
7. Your next step: Should you wait for this new drug?
The final verdict is clear: you should moderate your expectations of clascoterone. While it’s great to have another potential tool in the toolbox, it’s not the miracle cure it’s portrayed in the headlines. The evidence strongly suggests that they are less effective than treatments that are already on the market, affordable, and accessible today.
Delaying hair loss treatment is a big mistake. There is a chance of going backwards, and the longer you wait, the harder it will be to regain lost ground. Waiting months or years for a new medication that is likely to be less effective than current options means you lose hair and may never get it back.
conclusion
I hope Clascoterone proves to be a safe and beneficial option for some people. More options are always a good thing. However, marketing around recent trial results has been irresponsible and misleading. It preys on the hopes of people desperate for a solution. For now, your best bet is to stick with what we know works. Treatments like finasteride and minoxidil have decades of data and proven records of success. Don’t let the hype around a new product distract you from taking effective action today. Your future hair will thank you for it.
source: Rob English
